Hamidreza Montazeri Aliabadi1,2, Parvin Mahdipoor3, Cezary Kucharsky3, Nicole Chan3, Hasan Uludağ4,5,6. 1. School of Pharmacy, Chapman University, #211, 9401 Jeronimo Road, Irvine, California, 92618, USA. montazer@chapman.edu. 2. Department of Chemical & Material Engineering, Faculty of Engineering, University of Alberta, #2-020 RTF, Edmonton, Alberta, T6G 2G6, Canada. montazer@chapman.edu. 3. Department of Chemical & Material Engineering, Faculty of Engineering, University of Alberta, #2-020 RTF, Edmonton, Alberta, T6G 2G6, Canada. 4. Department of Chemical & Material Engineering, Faculty of Engineering, University of Alberta, #2-020 RTF, Edmonton, Alberta, T6G 2G6, Canada. huludag@ualberta.ca. 5. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada. huludag@ualberta.ca. 6. Department of Biomedical Engineering, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, T6G 2R3, Canada. huludag@ualberta.ca.
Abstract
PURPOSE: An alternative cancer therapy based on RNA interference (RNAi) has shown considerable promise but the possibility of resistance development is not known. This study explored the possibility of therapeutic resistance against siRNA nanoparticles in human cancer cells. METHODS: Two approaches to siRNA treatment were undertaken using lipid-modified polyethylenimines, a single high concentration (shock) and repeated increasing concentrations (gradual). The targets were Mcl-1, RPS6KA5 and KSP in MDA-MB-435 cells. RESULTS: There was no evidence of resistance development in shock-treated cells, while the decrease in mRNA levels of targeted proteins was not as robust in naïve cells in gradual treatment. However, silencing efficiency was restored after a 7-day recovery period when expression of suppressed proteins returned to normal levels. Cellular uptake of siRNA was not affected by pre-treatments. Other mediators involved in cell survival and proliferation were altered in siRNA-treated cells, but only JUN silencing led to a heightened loss of viability. In vivo experiments demonstrated similar silencing efficiency at mRNA level after repeat doses. CONCLUSIONS: Human cancer cells responded to repeat siRNA nanoparticles in a similar fashion after a temporary initial alteration and little, if any, resistance was evident against repeated siRNA treatments.
PURPOSE: An alternative cancer therapy based on RNA interference (RNAi) has shown considerable promise but the possibility of resistance development is not known. This study explored the possibility of therapeutic resistance against siRNA nanoparticles in humancancer cells. METHODS: Two approaches to siRNA treatment were undertaken using lipid-modified polyethylenimines, a single high concentration (shock) and repeated increasing concentrations (gradual). The targets were Mcl-1, RPS6KA5 and KSP in MDA-MB-435 cells. RESULTS: There was no evidence of resistance development in shock-treated cells, while the decrease in mRNA levels of targeted proteins was not as robust in naïve cells in gradual treatment. However, silencing efficiency was restored after a 7-day recovery period when expression of suppressed proteins returned to normal levels. Cellular uptake of siRNA was not affected by pre-treatments. Other mediators involved in cell survival and proliferation were altered in siRNA-treated cells, but only JUN silencing led to a heightened loss of viability. In vivo experiments demonstrated similar silencing efficiency at mRNA level after repeat doses. CONCLUSIONS:Humancancer cells responded to repeat siRNA nanoparticles in a similar fashion after a temporary initial alteration and little, if any, resistance was evident against repeated siRNA treatments.
Entities:
Keywords:
cancer therapy; polymeric carriers; resistance; siRNA
Authors: F Chang; L S Steelman; J T Lee; J G Shelton; P M Navolanic; W L Blalock; R A Franklin; J A McCubrey Journal: Leukemia Date: 2003-07 Impact factor: 11.528
Authors: Shankar Sellappan; Rebecca Grijalva; Xiaoyan Zhou; Wentao Yang; Menashe Bar Eli; Gordon B Mills; Dihua Yu Journal: Cancer Res Date: 2004-05-15 Impact factor: 12.701
Authors: Ahcène Boumendjel; Hélène Baubichon-Cortay; Doriane Trompier; Thomas Perrotton; Attilio Di Pietro Journal: Med Res Rev Date: 2005-07 Impact factor: 12.944
Authors: Koen Raemdonck; Roosmarijn E Vandenbroucke; Joseph Demeester; Niek N Sanders; Stefaan C De Smedt Journal: Drug Discov Today Date: 2008-08-07 Impact factor: 7.851
Authors: Mahsa Mohseni; Cezary Kucharski; Remant Bahadur K C; Mohammad Nasrullah; Xiaoyan Jiang; Hasan Uludağ; Joseph Brandwein Journal: PLoS One Date: 2021-06-22 Impact factor: 3.240